RAPID COMMUNICATION Adoptive Immunotherapy Evaluating Escalating Doses of Donor Leukocytes for Relapse of Chronic Myeloid Leukemia After Bone Marrow Transplantation: Separation of Graft-Versus-Leukemia Responses From Graft-Versus-Host Disease by Stephen Mackinnon et al.
RAPID COMMUNICATION 
Adoptive  Immunotherapy  Evaluating  Escalating  Doses  of Donor  Leukocytes 
for  Relapse  of  Chronic  Myeloid  Leukemia  After Bone  Marrow 
Transplantation:  Separation  of Graft-Versus-Leukemia  Responses From 
Graft-Versus-Host  Disease 
By Stephen Mackinnon,  Esperanza B. Papadopoulos,  Matthew H.  Carabasi, Lilian Reich, Nancy H. Collins, 
Farid Boulad, Hugo Castro-Malaspina, Barrett H. Childs, Alfred P.  Gillio, Nancy  A.  Kernan, Trudy N. Small, 
James W. Young,  and  Richard J. O'Reilly 
Infusions  of  large  numbers  (>lO"/kg)  of donor  leukocytes 
can induce  remissions in patients with chronic myeloid  leu- 
kemia (CML) who relapse after marrow transplantation. We 
wanted to  determine if substantially lower numbers of do- 
nor leukocytes could induce  remissions and,  if so,  whether 
this  would  reduce the 90%  incidence of  graft-versus-host 
disease (GVHD) associated with this therapy.  Twenty-two 
patients with relapsed CML were studied:  2 in molecular 
relapse, 6 in cytogenetic relapse,  10 in chronic phase, and 4 
in accelerated phase.  Each  patient received escalating doses 
of  donor  leukocytes at 4- to  33-week intervals.  Leukocyte 
doses were calculated as  T  cells per kilogram of recipient 
weight. There were 8 dose levels between 1 x  lo5  and 5  x 
10'. Lineage-specific chimerism and residual  leukemia  detec- 
tion  were assessed using sensitive polymerase chain reac- 
tion  (PCR)  methodologies.  Nineteen  of  the 22  patients 
achieved remission. Remissions were achieved at  the  follow- 
ing T-cell doses: 1 x  lo7  (n = 8).  5  x  lo7  (n = 4). 1 x  10" (n 
= 3).  and 5  x  10" (n = 4). To date,  15 of  the  17 evaluable 
ONE MARROW transplantation (BMT) is the treatment 
of  choice for patients with chronic myeloid leukemia 
(CML) who have a suitable bone  marrow donor. The success 
of allogeneic BMT is limited by the morbidity and mortality 
caused by graft-versus-host disease (GVHD), a complication 
that can be  prevented by  the removal of  T cells from the 
donor marrow. A higher incidence of  relapse has been re- 
ported  for  T-cell-depleted  grafts  as  compared  with 
unmanipulated BMT, suggesting that the removal of T cells 
from the donor marrow  not only results in a lower incidence 
of GVHD but also in a loss of a graft-versus-leukemia (GVL) 
effect.' 
The management of relapsed CML after T-cell-depleted 
BMT is difficult because cytotoxic drugs and (Y  interferon 
(aIFN)  are seldom curative'  and  second bone marrow trans- 
plants are  associated with a high regimen-related mortality 
and poor survival rates?  The remissions induced with the 
use of  donor leukocyte infusions for treatment of  relapsed 
CML  initially reported  by  Kolb et  a14  have  subsequently 
been  confirmed  by  other   investigator^.^"^  However,  this 
GVL effect of donor leukocytes has been  associated with a 
90% incidence of  GVHD in patients who achieved remis- 
 ion.^"' The GVHD observed in the patients who received 
adoptive immunotherapy is assumed to  be initiated by  the 
large numbers of  alloreactive donor T cells (median, >l X 
lO*/kg recipient weight) in  the leukocyte  infusion^.^"' 
We hypothesized that lower numbers of donor leukocytes 
might be able to mediate a GVL effect and achieve remission 
of relapsed CML without precipitating the high incidence of 
GVHD previously reported. We therefore designed a step- 
wise dose escalation trial to assess whether the antileukemic 
B 
Blood, Vol86. No 4  (August 15), 1995 pp 1261-1268 
patients have become BCR-ABL negative by PCR.  The inci- 
dence of GVHD was  correlated with the dose of T cells ad- 
ministered.  Only  1 of  the  8 patients  who  achieved remission 
at a T-cell dose of 1 x  107/kg developed GVHD,  whereas 
this complication  developed in 8 of the 11 responders who 
received a T-cell dose of z5  x  107/kg. Three patients  died 
in remission, 1 secondary to  marrow aplasia, 1  of  respiratory 
failure,  and 1 of complications  of chronic GVHD.  Sixteen 
patients  who  were  mixed  T-cell chimeras before treatment 
became full donor T-cell chimeras at  the  time  of remission. 
Donor  leukocytes  with a T-cell content as low as 1 x  lo7/ 
kg  can result in complete  donor  chimerism together with a 
potent  graft-versus-leukemia (GVLI effect. The dose of  donor 
leukocytes or T cells  used  may be important in determining 
both  the  GVL response and  the  incidence of GVHD. In many 
patients, this  potent  GVL effect can occur in  the  absence of 
clinical GVHD. 
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effect  of  donor leukocyte infusions could be  achieved at 
T-cell doses lower than  that  which  would  induce clinical 
GVHD. 
PATIENTS AND  METHODS 
Patients.  Twenty-two patients with relapsed CML after alloge- 
neic  BMT were studied. Details of  the patient characteristics are 
shown in Table 1. Donor-recipient pairs were matched at the  human 
leukocyte antigen A, B, and DR loci. The patients were conditioned 
with  12  X  125 cGy fractionated total body  irradiation + 120 m@ 
kg cyclophosphamide IT  10  mgkg thiotepa or 750 m@mz VP-16. 
All patients received a T-cell-depleted  marrow  graft." Clinical pro- 
tocols were approved by the Institutional Review Board  of Memorial 
Sloan Kettering Cancer Center and transplantsfleukocyte infusions 
were performed with the informed consent of each of  the patients. 
Donor leukocyte treatment.  No immunosuppressive drugs were 
administered before or after the leukocyte infusions. Nine patients 
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Table 1.  Patient  Characteristics 
CML Phase at  BMT to 1st 
MO  From 
Age  (yrM  Donor Type/  CML Phase at  GVHD Post-BMT  MO  From BMT  Leukocyte  Leukocyte  CML Therapy Before and 
BMT  (acute/chronic)  to Relapse  Infusion  Infusion  After Leukocyte Infusions  UPN  Sex  Sex 
859  42/M 
1245  36M 
1562  48/M 
1226  56/M 
1001  44/M 
1209  3WM 
1105  63/M 
946  29/M 
1311  46/M 
818  35/F 
986  13lF 
983  25lF 
1328  38lM 
546  41M 
1255  26lM 
1083  42lM 
852  23/M 
1118  41F 
1441  40lM 
1316  53/M 
1340  35/M 
1214  47/F 
SiblingM 
SiblingM 
Unrelated/M 
SiblingIM 
Sibling/M 
Sibling/M 
SiblingIM 
SiblingfF 
ParenVF 
Sibling/M 
Sibling/M 
SiblingF 
SiblingF 
Sibling/F 
Sibling/M 
SiblingIM 
Sibling/M 
Sibling/M 
SiblinglF 
SiblinglF 
Sibling/M 
SiblinglM 
Chronic 
Chronic 
Accelerated 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Nillnil 
Nillnil 
Ilnil 
Nillnil 
Nihil 
Nillnil 
Nillnil 
Nihil 
Ilnil 
Nillnil 
Nihil 
Nillnil 
Nil/nil 
Nillnil 
Nillnil 
Nihil 
Nihil 
Nillnil 
Nillnil 
Nihil 
Nihil 
Nillnil 
12 
9 
6 
3 
25 
12 
12 
12 
3 
11 
36 
36 
6 
36 
12 
33 
66 
35 
12 
21 
- 
- 
Accelerated 
Accelerated 
Accelerated 
Accelerated 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Chronic 
Cytogenetic 
Cytogenetic 
Cytogenetic 
Cytogenetic 
Cytogenetic 
Cytogenetic 
Molecular 
Molecular 
51 
11 
14 
13 
34 
15 
23 
44 
9 
50 
31 
39 
13 
103 
17 
34 
68 
37 
13 
21 
21 
22 
Hydroxyurea/anagrelide 
Hydroxyurea 
Hydroxyurea 
Hydroxyurealanagrelide 
Hydroxyurea/interferon 
Interferon 
Hydroxyurealinterferon 
Hydroxyurea 
Hydroxyurea 
Interferon 
None 
None 
Hydroxyurea 
None 
None 
None 
None 
None 
None 
None 
None 
None 
with  hematologic  relapse  of  CML  remained  on oral cytotoxic  treat- 
ment for control of  blood  counts  (eg,  hydroxyurea  or  anagrelide) 
without  dose  alteration.  Four  patients  received  aIFN. Patient UPN 
878 was  on  aIFN before  the  leukocyte  infusions  and  remained  on 
treatment  until  hematologic  remission.  Three  patients  (UPNs  1001, 
1209,  and  1105)  began  aIFN  treatment 64  to 78 weeks after  their 
first  donor  leukocyte  infusion  (Fig  1A).  The  donors  underwent  leu- 
kapheresis  with  the  Fenwal  CS3000  apheresis  system  (Baxter,  Deer- 
field, IL). The  T-cell  dose  administered  was  calculated  according  to 
the  following  formula:  total  nucleated  cells  X percentage  CD3+  cells 
per  kilogram  of recipient  weight.  The  percentage  of CD3+  cells  was 
determined  using  a  fluorescein  isothiocyanate  (FlTC)-conjugated 
CD3-specific  monoclonal  antibody  (Leu  4;  Becton  Dickinson, 
Mountain  View,  CA)  with  a  FACScan  cell  analyzer  (Becton  Dickin- 
son).  There  were  8 planned  dose  levels  (T cellslkg  recipient  weight) 
on  the  treatment  protocol:  1  X  I@, 5 X  l@,  1 X  IO6, 5  X  IO6, 1 X 
lo7, 5  X  lo7, 1 X  loa, and 5 X  10'. 
The  first  10  patients  began  treatment  at  a  T-cell  dose  of  1  X  IO5/ 
kg,  a  dose  selected  because it represents  the  number  of  clonable  T 
cells  that, if  administered  on  the  day  of  transplant, is able to cause 
GVHD.''  Because  no  responses  were  documented  within  18 weeks 
of receipt of a  T-cell  dose  of S  1 X 106kg,  the  subsequent  12  patients 
began  treatment  at  a  T-cell  dose  of  1  X  107/kg. The  actual  T-cell 
and  nucleated  cell  doses  infused  together  with  the  times  of  adminis- 
tration  are  shown  in  Table  2.  A  single  patient  (UPN  1001)  received 
additional  donor  leukocytes  with  a  T-cell  content  of  1.6  X  108/kg 
46 weeks  after  completion  of  the  leukocyte  escalation  (Fig  1A).  The 
time  interval  between  doses  was  a compromise  between  allowing 
each  dose  to have  sufficient  time  to  show  a  GVL  effect  and  the 
practical  consideration  of  attaining  remission  before  the  patients' 
leukemia  progressed  to blast  crisis.  The  median  time  interval  be- 
tween  leukocyte  dose  escalations  was  6 weeks (range,  4 to 33 weeks) 
but  was  only  5 weeks for patients  receiving  sl  X  107kg  and 9 
weeks  for  patients  receiving  z5  X  107/kg.  Eight  of  the  last  12 
patients  entered  on  study  received  only  a  single  dose  of  donor  leuko- 
cytes with a  T-cell  content  of  1 X  107kg. 
Evaluation of patient response.  Patients  were  evaluated  every  1 
to  4 weeks  after  the  leukocyte  infusions  for  evidence  of  GVHD. 
Complete  blood  counts,  serum  electrolytes,  and  liver  function  tests 
were  obtained  weekly.  Bone  marrow  aspirates  were  performed  be- 
fore  starting  leukocyte  therapy,  before  each  dose  escalation,  and  at 
the  time  of  clinical  response  to  assess  morphology,  cytogenetics, 
and  minimal  residual  disease. 
Acute  and  chronic  GVHD  were  classified  according  to  standard 
criteria  that  have  been  previously  de~cribed.'~.'~  Marrow  aplasia  was 
defined  by  the  presence  of  pancytopenia  (neutrophils,  <500/pL; 
platelets,  <2OlpL)  in  the  setting of  a hypocellular  bone  marrow. 
Defiirion of remission  The  results are presented as of  March  3 1, 
1995.  Hematologic  remission  was  defined as a return  to  normal  blood 
counts  and  bone  marrow  cellularity  in  the  absence  of  antileukemic 
therapy.  Cytogenetic  remission  was  considered to be  present  when  all 
bone  marrow  metapbases  were  normal.  In each case,  whenever  possible, 
at least  20  metaphases were examined. 'Ihe finding  of  a single  Philadel- 
phia  (€'h)-positive  metaphase  at  any  time  was  defined  as cytogenetic 
relapse.  Patients mated for  molecular  relapse  had to have two com- 
tive  positive  results  for  polymerase  chain  reaction  (PCR) assays for 
BCR-ABL  mRNA  from  both  bone marrow  and  peripheral  blood  at 
least 3 months apaa.  Molecular  remission  was  defined as the absence 
of  BCR-ABL  mRNA transcripts in bone marrow and peripheral  blood 
using  reverse  transcriptasePCR  as described below. 
Molecular analysis of chimerism and residual disease.  To assess 
chimerism,  high  molecular  weight  DNA  was  extracted  from periph- 
eral  blood  obtained  from  the  donor  and  recipient  before  the  trans- 
plant.  DNA  was  extracted  from  purified  peripheral  blood  granulo- 
cytes  and T cells  before  and  after  the  leukocyte  infusions  to  allow 
assignment  of  lineagespecific  chimerism,  as  previously  de- 
~cribed.'~"~  Minisatellite PCR  was  used  to  determine  ~himerism.'~ 
PCR  product  was  electrophoresed  on  agarose  gels  and,  after  Southern IMMUNOTHERAPY USING DONOR  LEUKOCYTES  1263 
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Table 2.  Details of Nucleated  Cell and  T-Cell Doses Infused  and Time Intervals Between Dose Emlation 
T-cell Dose  Nucleated Cell 
Weeks From Prior 
Leukocyte 
Infusion 
Weeks From Prior 
Leukocyte 
UPN 
T-cell Dose  Nucleated Cell 
per kg  Dose per kg  UPN  per kg  Dose per kg  Infusion 
1245 
1562 
1226 
1001 
1209 
1105 
859  1 X  105 
1 x 108 
5 x 108 
5  x 10’ 
1 x 108 
1.9 x 108 
5  X  105 
1 X  107 
1 X 105 
5  X 105 
1 X  lo7 
3  X  107 
1 x 108 
4.8 X  10’ 
1 X  10’ 
1 X 105 
5  X  105 
1 x 106 
5  x 106 
5  x 106 
5  x 10’ 
1 x 108 
1 X  105 
5  X  105 
1 x 106 
5  x 106 
1 X  107 
5  X  107 
1 x 108 
3.6 X  10’ 
1 X  105 
5  X  105 
1 X  107 
5  X  107 
1 x 106 
1 x 108 
5  x 105 
1 x 105 
5  X  105 
1 x 106 
5  x  106 
5  x 10’ 
0.8 X  10’ 
4.5 x 108 
946  1 X  105 
1 X  107 
5  X  105 
5  X  105 
2.5 x  lo6 
5  x 106 
1.4  X  107 
2.8 X  107 
1.4 x 10’ 
3.3 x 108 
12.7 x 10’ 
1.8 X  105 
8.9 X  105 
1.8 X  107 
6.7  X  107 
2.6 x  lo8 
10 x 108 
2.5 x 10’ 
2.1 X  105 
10.7 X  105 
2.1 x 106 
10.7 x lo6 
10.7 x  lo6 
11.1  X  107 
2.2  x 108 
1.9 X  105 
9.4  X  105 
1.9 x 106 
9.4  x 108 
1.7 x 10’ 
10.2 x 10’ 
2.2 x 108 
9.7 x 108 
1.6  X  105 
7.9  X  105 
1.9 X  107 
10.4  X  107 
1.8 x 10‘ 
1.9 x 108 
9.7 x 108 
1.9 X  105 
9.3 X  105 
1.9 x 106 
9.3 x 106 
1.2 x 108 
1.6 X  10’ 
12.8 X  10’ 
1.9 X  107 
1.7 X  105 
8.6  X  lo5 
- 
4 
5 
4 
4 
5 
5 
33 
- 
10 
6 
4 
9 
10 
- 
- 
4 
4 
4 
7 
6 
10 
- 
4 
6 
5 
5 
10 
7 
17 
- 
14 
8 
6 
6 
7 
17 
- 
6 
6 
8 
9 
10 
9 
16 
- 
5 
946 
1371 
878 
986 
983 
1328 
546 
1255 
1083 
852 
1118 
1447 
1376 
1340 
1274 
1 x 106 
5  x 108 
5 x 10’ 
1 x 108 
4  x 108 
1 X  107 
1 X  107 
5  X  107 
0.9 x 108 
4.8 x 10’ 
1 X  105 
5  X  105 
1 x 106 
5  x 106 
1 x 10’ 
1 x 108 
5  X  107 
1 X  105 
5  X  lo5 
l x 106 
5 x 106 
1 X  lo7 
5  X  107 
1 X  105 
5  X 105 
1 x 106 
1 x 10’ 
5  X  107 
1 x 10’ 
1 x 108 
5  X  10’ 
1 X  107 
5  X  107 
1 X  107 
5  X  lo7 
1 X  lo7 
1 X  107 
1 X  lo7 
1 X 107 
1 X  10’ 
1 X  lo7 
1 X  107 
1.7  X  lo6 
8.6  X  IO6 
3.7 X  lo7 
2  x 108 
2.4 x 10’ 
11.4  x 10’ 
2  x 10’ 
1.2 x 108 
1.9 x 108 
10.9 x 108 
3.2 X  105 
1.6 X 10‘ 
3.2 x  lo6 
1.6 X  10’ 
1.3 x 10’ 
2.3 X  10’ 
3.2 X  107 
2.4 X  lo5 
1.2 x  lo6 
2.4 X  lo6 
1.2  X  lo7 
3.2 X  107 
3  X  105 
1.3 X  10’ 
1.5 X  lo6 
3  x 106 
3  X  lo7 
1.3  X  10’ 
2.3 X  10’ 
9.2 x 10’ 
2.1 x  lo8 
1.9  X  lo7 
8.7 X  lo7 
1.9  X  107 
1.2 x  lo6 
2  x 10’ 
2  X  107 
1.6 X  10’ 
1.7 X  lo7 
1.5  X  lo7 
2.4 X  lo7 
2.1 X  10’ 
6 
4 
7 
5 
10 
11 
- 
8 
8 
13 
- 
7 
4 
6 
5 
8 
4 
- 
4 
4 
4 
5 
5 
- 
5 
7 
6 
6 
- 
9 
12 
- 
10 
- 
8 
- 
- 
- 
- 
- 
- 
- 
transfer to nylon membranes,  was  hybridized  with  32P-labeled  oligo-  between 2 and 5 pg of total RNA was  added  to  a  reverse  transcriptase 
nucleotide  probe  and  autoradiographed.  The  sensitivity of detecting  reaction.  A  nested  PCR  technique  was  used,  as  previously  de- 
mixed  chimerism  with  this technique is between 0.1%  and  l%  de-  scribed.’*  PCR  product  was run on  an  ethidium  bromide-stained  2% 
pending  on  the  primers  used  and  the  length  of  the  allele being  agarose  gel and visualized  under  UV  light. Using this  approach,  we 
amplified. No attempt  was  made  to  quantitate  mixed  chimerism.  can  detect  a single control-positive (K562) cell in lo6  normal cells. 
To detect BCR-ABL transcripts,  RNA  was  prepared  from  periph-  Elaborate  measures  were  taken  to  minimize  contamination  and  the 
era1 blood  and  bone  marrow  buffy  coat  cells. To prepare  the  cDNA,  recommendations of  Kwok  and  Higushi’’  have  been  adopted. IMMUNOTHERAPY  USING  DONOR  LEUKOCYTES  1265 
Table 3.  Results  Indicating  Time to Remission, GVHD, and  Chimerism 
~  ~~  ______  ~~  ~  ~  ~  ~~  ~ 
Weeks From Last 
Weeks  From Last  Weeks From Last  Leukocyte Infusion 
Leukocyte Infusion to  Leukocyte Infusion to  to Molecular  GVHD  T-cell Chimerism Before  T-cell Chimerism After  follow-Up 
Duration of 
UPN  Hematologic Remission  Cytogenetic Remission  Remission  (acutelchronicl  Leukocyte Infusions  Leukocyte Infusions  (wk) 
859 
1245 
1562 
1226 
1001 
1209 
1105 
946 
1371 
878 
986 
983 
1328 
546 
1255 
1083 
852 
1118 
1441 
1376 
1340 
1274 
No  remission 
No remission 
4 
10 
52 
33 
8 
3 
No remission 
2 
3 
2 
3 
11 
- 
- 
- 
- 
- 
- 
- 
- 
- 
No metaphases 
17 
54 
33 
10 
6 
- 
5 
4 
7 
5 
11 
6 
12 
16 
19 
14 
6 
- 
- 
NE 
37 
NA 
31 
16 
NE 
- 
- 
13 
31 
16 
16 
13 
16 
20 
NA 
19 
14 
12 
17 
Nil/nil 
Nil/nil 
NiI/NE 
Nil/limited 
Nil/limited 
Nil/nil 
Nil/extensive 
Nil/nil 
Nilhi1 
Il/limited 
Nil/nil 
Nil/extensive 
Nil/limited 
Nil/limited 
Nil/extensive 
Nil/nil 
Nil/nil 
Nil/nil 
Nilhi1 
Nil/limited 
Nil/nil 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
NE 
Donor 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Mixed 
Donor 
Donor 
Donor 
Donor 
Donor 
Donor 
Mixed 
Donor 
Donor 
Donor 
Donor 
NE 
Donor 
Donor 
Mixed 
Donor 
Donor 
Donor 
Donor 
112+ 
87 t 
10 
97 t 
108+ 
95+ 
106+ 
59 
55 
106+ 
103+ 
89 + 
67 + 
46 
59  + 
64+ 
38+ 
38 + 
20+ 
17+ 
36+ 
-  -  14  Nilhi1  Mixed  Donor  33+ 
Abbreviations:  NE,  not evaluable; NA, not achieved at last follow-up 
RESULTS 
Response of CML.  Nineteen of the 22 patients achieved 
remission. Three patients failed  to  respond; the  2  nonre- 
sponders treated in  accelerated phase  have progressed to 
blast crisis. The times to hematologic remission, cytogenetic 
remission, and molecular remission are shown in Table 3. 
Remissions were achieved at the following cell doses: 1 X 
lo7  (n = 8), 5 x lo7  (n = 4), 1 X  10'  (n  = 3), and 5 X  10" 
(n = 4). Although we can be certain that 8 of  the patients 
entered remission after a single dose of leukocytes with a 
T-cell content of  1 X  107/kg,  the specific leukocyte dose or 
doses that resulted in remission induction in the 11 respond- 
ers  who  received multiple  leukocyte infusions cannot be 
identified with certainty. For example, UPN 1255 had cyto- 
genetic evidence of  response after the first dose of leukocytes 
with a T-cell content of  1 X  107/kg (Fig lB), and 5 of  the 
other 10 responders entered hematologic remission within 2 
to 3 weeks of receiving their last donor leukocyte infusion 
(Table 3), suggesting that either they had a very rapid re- 
sponse to  the  last dose of leukocytes or that their responses 
were mediated by  the prior dose or doses of  donor leuko- 
cytes. 
Three patients with hematologic relapse had delayed re- 
sponses (74 to 108 weeks) to the donor leukocytes infusions. 
All 3 of  these patients were  began  nIFN  therapy after ini- 
tially failing to  respond to  donor  leukocytes alone. UPN 
1105 began aIFN  therapy at the time of the final leukocyte 
infusion, whereas UPNs  1001 and  1209 received nIFN  22 
and 18 weeks after a failure to respond to donor leukocytes 
with a T-cell content of 3.6 to 5 X  108/kg  (Fig 1A). 
Serial cytogenetic studies performed before and after do- 
nor leukocyte infusions showed the disappearance of the Ph 
chromosome in responders who had hematologic or cytoge- 
netic relapse (Fig l). With the exception of  UPNs  11  18  and 
1447, all patients had evidence of  residual leukemia on PCR 
analysis at the time of  documented cytogenetic remission. 
Fifteen of the 17 evaluable patients have become PCR nega- 
tive for BCR-ABL mRNA at 12 to 37 weeks after their last 
donor leukocyte infusion (Fig 1). 
Chimerism.  The results of the PCR studies to detect chi- 
merism are summarized in Table 3. Twenty patients were 
mixed T-cell chimeras before the donor leukocyte treatment. 
At each dose level at which the patients'  leukemia did not 
go into remission, the T  cells remained mixed  chimeric; 
however, on entering remission, the host T cells were no 
longer detectable (Fig 2). After remission induction, all re- 
sponders had granulocytes exclusively of donor origin (Fig 
2). Sixteen of  the  17 responders who were mixed  T-cell 
chimeras before treatment became full donor T-cell chimeras 
on entering remission. There was no change in myeloid or 
T-cell chimerism in the nonresponders. 
Toxicity.  There  were  3  treatment-related  mortalities. 
One patient (UPN 1562) developed marrow aplasia and re- 
ceived a T-cell-depleted  donor marrow boost but died of 
sepsis within 14 days of  marrow infusion without evidence 
of engraftment. Four other patients (UPNs 1226,1001,1209, 
and 1105) developed transient aplasia that resolved sponta- 
neously without the need for donor marrow infusion. The 
second death was in  a patient (UPN 946) who developed 
progressive respiratory failure with onset at the time of cyto- 
genetic remission. No infective etiology for this deterioration 
was found either antemortem or at autopsy. Microscopy of 1266  MACKINNON ET  AL 
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Fig 2.  Sequential studies before and after donor leukocyte infu- 
sions (cell doses indicated are donor T cells per kilogram). Pretrans- 
plant donor  and recipient DNA together with  post-BM1  granulocyte 
(Grans) and T cells were amplified for 30 cycles  using  primers for 
minisatellite 33.6 (UPN 986). The patient was a mixed T-cell  chimera 
before treatment. The granulocytes were mostly of  recipient  origin 
before treatment in patients with hematologic  relapse. The granulo- 
cytes  became  exclusively  of  donor  origin in all patients on  remission 
induction. Mixed T-cell chimerism persisted  in patients receiving es- 
calating  doses  of  T cells until remission induction  was achieved when 
the T cells  became  exclusively  of  donor  origin. 
the lung showed adult respiratory distress syndrome with  no 
evidence of  lymphocytic infiltration. The third death (UPN 
546) was secondary to complications of chronic GVHD.  A 
fourth patient (UPN 137 I ) who  had received a splenectomy 
before transplant and who was noncompliant with his peni- 
cillin prophylaxis died  in chronic phase of  pneumococcal 
sepsis. 
The relationship between the dose of T cells administered 
and the incidence of GVHD  observed is shown in Table 4. 
As can  be seen, no patient developed GVHD  after leukocyte 
infusions containing T-cell doses 4  X  106kg. Of  the 21 
patients who received the T-cell dose of  1  X  IO'kg, only 
one (UPN 1376) developed limited chronic GVHD.  Fourteen 
patients received leukocyte infusions with a T-cell dose of 
25  X  107/kg  and  8  developed chronic GVHD.  The com- 
monest presentation of  chronic GVHD  was oral mucositis, 
which was seen in 6 of the 9 patients. Chronic GVHD  was 
treated  with  corticosteroid  therapy  t azathioprine  or 
cyclosporine A. One patient developed grade I1 acute GVHD 
after a leukocyte infusion with a T-cell content of  1  X  IOx/ 
kg. 
DISCUSSION 
In  this study we  have shown  that  the number of  donor 
leukocytes administered to  patients with  relapse of  CML 
after BMT may  be  important in mediating a GVL  response. 
In  contrast to previous studies in which  the  median  dose of 
donor leukocytes administered to patients was  3.8  X  IO%g 
(range, 0.34 to  12.3  X  10xkg)?"' this report  has  clearly 
shown that donor leukocytes with  a T-cell content of  only 
I  X  107kg are capable of  inducing remissions. These are 
the lowest numbers of donor leukocytes that  have ever been 
documented to induce remissions in patients with CML who 
relapse after BMT. 
Although donor leukocyte therapy has resulted  in a remis- 
sion rate in excess of  70% in patients with  relapse  of CML 
after BMT, it has been associated with a significant  morbid- 
ity and  mortality."'  The major toxicities of  this treatment  are 
secondary to marrow aplasia and GVHD,  which may occur 
in up to 50% and 90% of  responders, respectively.'""'  The 
low incidence of GVHD  seen in this report may  be  a related 
to the relatively  low  number  of  donor leukocytes that  were 
used  to  achieve remission because the majority of  our pa- 
tients received fewer leukocytes than  in most  other stud- 
ies:""  In  support of  this concept was  the  absence of either 
acute or chronic GVHD  seen in 7 of  8 of our patients who 
achieved remission after receiving a single dose of  leuko- 
cytes with a T-cell content of  1  X  IO7kg (Table 4). 
In  previous studies, patients who  were  not  receiving im- 
munosuppression had a median time interval  from  receiving 
a single treatment course of donor leukocyte  infusion  therapy 
to  cytogenetic  remission  of  13  weeks  (range,  4  to  34 
 week^).^,^"' In our study, the 8 patients who  responded  to  the 
single dose of  donor leukocytes with  a T-cell content of  1 
X  IO7kg had  a median  time  interval  to  either cytogenetic 
or molecular remission of  14  weeks (range, 4 to 19 weeks), 
suggesting that  lower doses  of  donor  leukocytes did  not 
result  in a delayed GVL response. Whereas some of  the 
patients who subsequently received higher doses of  leuko- 
cytes may have  responded  to leukocytes with a T-cell content 
of  1  X  IO7@  if  a longer time  interval  between  leukocyte 
doses had  been  allowed, other patients, such as UPNs 1328, 
946, 1226, 1 105, 1209,  and  1001, waited 26, 32, 33, 45.  63, 
and 88 weeks, respectively, from receiving donor leukocytes 
with a T-cell content of  1 X  107kg  to cytogenetic remission. 
Therefore, either these patients had  a markedly  delayed  re- 
sponse to the  1  X  IO'kg  cell dose or they  obtained their 
remissions from the higher doses of donor leukocytes they 
subsequently received. In addition, IO of  our patients began 
dose escalation at  1  X  l@ T cellskg, with  8  of  them  ulti- 
mately achieving cytogenetic remission. In these 8 patients, 
Table 4.  Relationship Between T-cell Dose, 
Leukemia  Remissions,  and GVHD 
No. of Patients 
This Cell Dose 
Treated With 
Doseikg 
T-cell 
GVL Effect  GVHD 
1 X  105 
5 X  105 
1 x 108 
5 x 106 
1 x 10' 
5 x 10' 
21  x 106 
10 
10 
9 
8 
21 
14 
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the minimum times between receiving donor leukocytes with 
a T-cell content of  51  X  106/kg and entering cytogenetic 
remission were  18, 19, 28, 43, 44,  62, 69, and 98 weeks. 
Therefore, either these patients responded to donor leuko- 
cytes with a T-cell content of  51  X  106/kg  and include the 
slowest responders ever documented or these donor leuko- 
cyte doses are in most patients insufficient to mediate a GVL 
effect. These data suggest that either low doses of  donor 
leukocytes are associated with a delayed GVL response or 
there is a relationship between donor leukocyte dose and 
response to adoptive immunotherapy. 
The factors  that  determine which patients  will achieve 
remission with donor leukocytes, and at what dose, are cur- 
rently  unknown. One factor might be  the alloreactivity in 
the graft-versus-host direction and therefore a function of the 
different frequencies of alloreactive precursors seen among 
HLA-identical donor-recipient sibling  Secondly, it 
has been suggested by  other groups that the phase of  CML 
or the size of the tumor cell burden could be a predictor of 
res~onse.~  Our  data,  although  not  statistically significant, 
would  tend  to  support this hypothesis. Whereas only 2 of 4 
accelerated-phase  patients  achieved  remission,  9  of  10 
chronic-phase patients and all 8 patients with cytogenetic or 
molecular relapse responded. In  addition, there was also a 
suggestion that patients with chronic- or accelerated-phase 
disease required more donor leukocytes to achieve remis- 
sion. However, we have previously shown that 2 patients 
with  only  molecular evidence of relapse of  CML when re- 
ceiving donor leukocytes with a T-cell content of less than 1 
X  IO%g  used to successfully treat Epstein-Barr virus (EBV) 
lymphoproliferative disease ultimately had hematologic re- 
lapse  45  and  52  weeks  after  adoptive  irnmun~therapy.'~ 
Thirdly, the role of aIFN  in potentiating the effect of donor 
leukocytes remains unclear. Our data clearly show that most 
patients do not require aIFN to respond to donor leukocyte 
therapy;  however, the responses seen in  UPNs  1001 and 
1209 suggest that IFN may  be essential for remission induc- 
tion  in  some patients. Lastly, the time interval from BMT 
to donor leukocyte infusion might be  an  important variable. 
We had previously shown that as few as 1 X  105/kg  T cells 
are capable of  causing GVHD if administered on the day  of 
transplant.'* This  study has  shown that most  patients can 
receive as  many  as  1  X  107/kg T  cells  29  months after 
T-cell-depleted  BMT without the development of  clinical 
GVHD. This difference in  the dose of  T cells required to 
initiate GVHD late after transplant is analogous to the obser- 
vations reported in  murine models of  allogeneic BMT.".*' 
Whether the  same  number  of  donor leukocytes could be 
administered without toxicity after a T-replete BMT is cur- 
rently  not known. It is therefore possible that a certain thresh- 
old  number of  donor T cells is necessary to obtain a GVL 
effect and that this threshold might be determined by a num- 
ber  of  factors including time  from  BMT, donor-recipient 
alloreactivity, and disease status of the CML. 
We have shown that mixed T-cell chimerism after BMT 
for CML is associated with the persistence of minimal resid- 
ual  disease and with cytogenetic or hematologic relapse.16 
Because the T cell is not  usually  part of the leukemic clone 
in CML,Zh-B  the persistence of  host T cells after transplant 
is a variable that is independent of detecting residual leuke- 
mia. Our findings of  a switch from mixed T-cell chimerism 
to all donor T-cell chimerism in patients achieving remission 
of  CML are similar to the results of the studies of Johnson 
et al,25  who have shown, in a murine model, that delayed 
infusion of  donor spleen cells after a T-cell-depleted  mar- 
row graft resulted in a conversion from mixed to full-donor 
T-cell chimerism together with a significant GVL effect. The 
finding that the donor leukocytes not only eradicate the host 
leukemia but also the host nonleukemic T cells suggests that 
the effector cells may not be leukemia-specific but, rather, 
are more  likely allo-specific. However, these data do not 
preclude the possibility that other immunocompetent media- 
tors, such as natural killer cells, which have been shown to 
have in  vitro anti-CML activity, could play  a role  in  the 
GVL re~ponse.~' 
Our data indicate that patients treated for cytogenetic or 
molecular relapse of CML may achieve remission with little 
or no toxicity when receiving donor leukocytes with a T- 
cell content of  1 X  107/kg.  This finding, if  confirmed in a 
larger group of patients, may  not only alter the way in which 
patients with post-BMT relapse of  CML receive adoptive 
immunotherapy but  could  also change the  way  in  which 
transplantation is used to cure this  disease. One approach 
would be to offer patients a T-cell-depleted  BMT with its 
low  incidence of  GVHD and  transplant-related mortality. 
Knowing that many  of  these patients would relapse without 
intervention,'  regular  follow-up with  PCR  would  be per- 
formed to detect residual CML. Adoptive immunotherapy 
with donor leukocytes would then be administered to patients 
who became PCR positive to achieve molecular remission. 
This might be a particularly useful approach in older patients 
who have the highest morbidity and mortality from GVHD 
and  who  constitute the majority of patients with CML.3' 
In summary, donor leukocyte infusions can induce remis- 
sions in patients with relapsed CML after BMT. The dose 
of donor leukocytes used  may to be important for determin- 
ing both GVL and GVHD. Remission induction is accompa- 
nied by  switch from mixed T-cell chimerism to having T 
cells exclusively of donor origin. The GVL activity of  these 
leukocytes is possibly mediated, at least in part, by alloreac- 
tive donor T cells. 
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